Gynecologic Cancers

Latest News

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.
Avutometinib Combo Yields Responses in Serous Ovarian Cancer Subgroups

March 26th 2024

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.
Nab-Sirolimus Yields Sustained Responses in Gynecologic Sarcomas

March 20th 2024

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.
CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.
Frontline Durvalumab Combo Improves PFS/DOR in Advanced Endometrial Cancer

March 19th 2024

More News